
Highlighting how technology and mindset shifts can help expand breast cancer research leadership beyond high-income countries and build more inclusive global trial networks.

Highlighting how technology and mindset shifts can help expand breast cancer research leadership beyond high-income countries and build more inclusive global trial networks.

Medidata deepens its collaboration with Sanofi to advance AI-enabled clinical development, while BioRender joins forces with Anthropic to power visual communication within Claude for Life Sciences.

Today’s ACT Brief explores how eConsent is modernizing participant engagement, highlights new data on global representation in breast cancer trials, and examines Moderna’s decision to halt its Phase III mRNA-1647 program after missing key endpoints.

Examining how shifting leadership patterns in breast cancer research signal growing international participation—and the continued need for broader equity in global trials.

As decentralized and hybrid trial models expand, eConsent is emerging as a critical tool for improving participant understanding, reducing site burden, and strengthening data integrity through digital automation, accessibility, and regulatory compliance.

In today’s ACT Brief, we revisit key insights from SCOPE Summit 2025 on AI and pragmatic trials, examine Genentech’s Phase III vamikibart data in uveitic macular edema, and highlight MJH Life Sciences’ acquisition of BPD Healthcare—expanding the bridge from discovery to delivery.

At AAO 2025, Genentech reported that vamikibart, a first-in-class IL-6–targeted antibody, led to rapid improvements in visual acuity and macular thickness in patients with uveitic macular edema, supporting its potential as a non-steroid treatment option.

Revisit top insights from SCOPE Summit 2025, where industry leaders explored how artificial intelligence is reshaping trial risk management and how pragmatic study designs are bridging the gap between clinical research and real-world care.

Today’s ACT Brief highlights how artificial intelligence is transforming trial data management, why biotechs are embracing parallel execution to accelerate development, and new Phase III results showing Imfinzi’s potential to redefine early-stage bladder cancer treatment.

How a unified approach to clinical data management, powered by artificial intelligence and advanced analytics, can elevate clinical trial monitoring and redefine how teams assess, act on and learn from data.

At ESMO 2025, AstraZeneca reported that Imfinzi plus BCG therapy reduced the risk of recurrence or death by 32% in patients with high-risk non-muscle-invasive bladder cancer, marking a potential new standard in early-stage disease.

Learn how early regulatory engagement, validated digital systems, and robust protocol design enable biotechs to run parallel studies without compromising compliance or data integrity.